Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

DPYD Sequencing Identifies More Clinically Relevant Variants as Compared to Targeted Genotyping.

Clinical chemistry - 3 Jun 2026

Moyer Ann M, Lundquist Emma, Thoreson Emily K, Kluge Michelle L, Kotzer Katrina E, Love Elyse M, Glessner Heather L, Arneson Sarah K, Langman Loralie J, Baudhuin Linnea M, Black John Logan

Abstract excerpt

BACKGROUND: DPYD testing can identify patients at risk for severe toxicity when a standard fluoropyrimidine antineoplastic dose is prescribed. Sequencing-based methods detect rare variants, which require classification. METHODS: DPYD sequencing results over a 9-year period through to 2024 were analyzed. The dataset was filtered to calculate the positive test rate for different genotyping strategies, including...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Dihydrouracil Dehydrogenase (NADP)
Share to DPYD gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Variation

Share to Genotype

Share to Genotyping Techniques

Share to Sequence Analysis, DNA

Source

Identifiers

PMID: 41802113
DOI: 10.1093/clinchem/hvag007

Genes

DPYD

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

DPYD Sequencing Identifies More Clinically Relevant Variants as Compared to Targeted Genotyping.PMID 41802113Read ↗

Real‐world study on fluoropyrimidine‐related toxicity outcomes in cancer patients with select DPYD variant alleles that received DPYD genotype‐guided dosingSemantic proximity Read ↗

Discovering novel germline genetic variants linked to severe fluoropyrimidine-related toxicity in- and outside DPYD.Semantic proximity Read ↗

Developing DPYD Genotyping Method for Personalized Fluoropyrimidines Therapy.Semantic proximity Read ↗

DPYD genotyping and predicting fluoropyrimidine toxicity: where do we stand?Semantic proximity Read ↗

Patients carrying DPYD variant alleles have increased risk of severe toxicity and related treatment modifications during fluoropyrimidine chemotherapy.Semantic proximity Read ↗

Diagnostic and Therapeutic Strategies for Fluoropyrimidine Treatment of Patients Carrying Multiple DPYD VariantsSemantic proximity Read ↗

Importance of and Strategies for Implementing DPYD Testing to Prevent Severe Fluoropyrimidine Chemotherapy Toxicity in Health Care Systems.Semantic proximity Read ↗

A predictive model for life-threatening fluoropyrimidine toxicity based on DPYD sequencing in colorectal cancer.Semantic proximity Read ↗

Clinical Implementation of Rare and Novel DPYD Variants for Personalizing Fluoropyrimidine Treatment: Challenges and OpportunitiesSemantic proximity Read ↗

Real-World Impact of an In-House Dihydropyrimidine Dehydrogenase (DPYD) Genotype Test on Fluoropyrimidine Dosing, Toxicities, and Hospitalizations at a Multisite Cancer Center.Semantic proximity Read ↗

DPYD genotyping and 5-fluoropyrimidine toxicity: An overview of systematic reviews protocol.Semantic proximity Read ↗

Optimizing fluoropyrimidine therapy: Real‐world impact of DPYD genotype‐based dosing on severe toxicity ratesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.